会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • 숙취 예방 또는 해소용 조성물
    • 组合物用于预防或缓解酒精性反应
    • KR101247927B1
    • 2013-03-26
    • KR1020120077421
    • 2012-07-16
    • 보령제약 주식회사
    • 김제학이중복이상훈이주한남윤선김윤식정주영
    • A23L33/00A23L1/30
    • A23L33/105A23V2002/00A23V2200/334
    • PURPOSE: A composition for preventing or relieving an alcoholic hangover is provided to have excellent alcohol decomposition ability and acetaldehyde decomposition ability. CONSTITUTION: A composition for preventing or relieving an alcoholic hangover comprises a water caltrop extract, a fermented extract of Artemisia capillaris Thunb, green leaves, mulberry leaves, balsam pear, kuzu vine, and lotus root, in which the Artemisia capillaris Thunb, green leaves, mulberry leaves, balsam pear, kuzu vine, and lotus root are fermented with a mixed spawn of Streptomyces thermophilus, Lactobacillus acidophilus, Saccharomyces cerevisiae, and Bacillus subtilis in a weight ratio of 1:1:1:1; and a rice embryo complex fermented extract, at a weight ratio of 1:75-175:1-8. The water caltrop extract is extracted with water, alcohol with 1-4 carbons, ethylacetate, chloroform, hexane, dichloromethane, or their mixture. The rice embryo complex fermented extract is obtained by fermenting rice embryo, rice bran, and soybean-originated peptide by at least one microorganism selected from the group consisting of Saccharomyces microorganisms, and Issatchenkia microorganisms. The Saccharomyces microorganism is at least one selected from the group consisting of Saccharomyces cerevisiae, Saccharomyces cerevisiae, and Saccaromyces bayanus. The issatchenkia microorganism is at least one selected from the group consisting of Issatchenkia orientalis and issatchenkia occidentalis. [Reference numerals] (AA) Alcohol; (BB) Rice embryo complex fermented extract; (CC) Caltrop + plant fermentation; (DD) Caltrop + plant fermentation + rice embryo complex fermented extract; (EE) Plant fermentation + rice embryo complex fermented extract; (FF) Caltrop + rice embryo complex fermented extract; (GG) Yeo-myoung 808(existing commercial product); (HH) Caltrop 400; (II) Plant fermentation
    • 目的:提供用于预防或缓解酒精宿醉的组合物以具有优异的醇分解能力和乙醛分解能力。 构成:用于预防或缓解酒精宿醉的组合物包括水葫芦提取物,青蒿的发酵提取物,绿叶,桑叶,苦瓜,竹子藤和莲藕,其中青蒿 以1:1:1:1的重量比混合产生嗜热链霉菌,嗜酸乳杆菌,酿酒酵母和枯草芽孢杆菌的混合产物,发酵桑叶,苦瓜,库竹藤和莲藕。 和水稻胚胎复合物发酵提取物,重量比为1:75-175:1-8。 水提取物用水,含有1-4个碳的醇,乙酸乙酯,氯仿,己烷,二氯甲烷或它们的混合物萃取。 所述水稻胚胎复合物发酵提取物是通过至少一种选自由酵母属微生物和伊曲霉属微生物组成的组的微生物发酵水稻胚,米糠和大豆来源的肽获得的。 酿酒酵母属微生物是选自酿酒酵母,酿酒酵母和八角豆(Saccaromyces bayanus)中的至少一种。 所述发酵微生物是选自东方Iss alis(Issatchenkia orientalis)和西洋蓟马(Issatchenkia occidentalis)中的至少一种。 (标号)(AA)醇; (BB)水稻胚胎复合发酵提取物; (CC)Caltrop +植物发酵; (DD)Caltrop +植物发酵+水稻胚胎复合发酵提取物; (EE)植物发酵+水稻胚胎复合发酵提取物; (FF)Caltrop +水稻胚胎复合发酵提取物; (GG)Yeo-myoung 808(现有商品); (HH)Caltrop 400; (二)植物发酵
    • 7. 发明公开
    • 혈관생성억제 작용을 갖는 신규한 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물
    • 新化合物,其制备方法和包含抗血清药物的药物组合物
    • KR1020130013163A
    • 2013-02-06
    • KR1020110074638
    • 2011-07-27
    • 보령제약 주식회사
    • 김지한김제학이준광정한선한남석박용강승훈정희진이경태최혜은지용하이주한백수희
    • C07D213/82C07D401/12A61K31/444A61P35/00
    • C07D401/14C07D213/82C07D401/12C07D413/14C07D417/14C07D495/04
    • PURPOSE: A pharmaceutical composition containing a compound which suppresses angiogenesis is provided to prevent and treat diseases caused by angiogenesis suppression abnormality. CONSTITUTION: A compound which suppresses angiogenesis is denoted by chemical formula I. The compound of chemical formula I or pharmaceutically acceptable salts thereof is 2-(1-benzylpiperidine-4-ylamino)-N-(3-chlorphenyl)nicotiamide[103] or pharmaceutically acceptable salts thereof. A method or preparing the compound of chemical formula I comprises a step of reacting a compound of chemical formula II and a compound of chemical formula III under the presence of a base. The base is triethyl amine, N,N-diisopropylethyl amine, N-methylmorpholine, DBU(1,8-diazabicyclo[5.4.0]undec-7-ene), N-methylpiperidine, 4-dimethylaminopyridine, N,N-dimethylaniline, 2,6-lutidine, 4-N,N-dimethylaminopyridine, or pyridine. A pharmaceutical composition for preventing or treating diseases or symptoms caused by VEGF(Vascular Endothelial Growth Factor) abnormality contains the compound of chemical formula I or the salts.
    • 目的:提供含有抑制血管生成的化合物的药物组合物,用于预防和治疗由血管发生抑制异常引起的疾病。 构成:抑制血管发生的化合物由化学式I表示。化学式I化合物或其药学上可接受的盐是2-(1-苄基哌啶-4-基氨基)-N-(3-氯苯基)烟酰胺[103]或 其药学上可接受的盐。 制备化学式I化合物的方法包括使化学式II化合物与化学式III化合物在碱存在下反应的步骤。 碱为三乙胺,N,N-二异丙基乙胺,N-甲基吗啉,DBU(1,8-二氮杂双环[5.4.0]十一碳-7-烯),N-甲基哌啶,4-二甲基氨基吡啶,N,N-二甲基苯胺, 2,6-二甲基吡啶,4-N,N-二甲基氨基吡啶或吡啶。 用于预防或治疗由VEGF(血管内皮生长因子)异常引起的疾病或症状的药物组合物含有化学式I的化合物或其盐。
    • 8. 发明公开
    • 아자시티딘의 전―동결건조 제제, 아자시티딘의 동결건조 제제 및 이의 제조방법
    • 丙烯酸的预冷冻干燥制剂,缩水甘油酯的制备及其制备方法
    • KR1020130009909A
    • 2013-01-24
    • KR1020110070567
    • 2011-07-15
    • 보령제약 주식회사
    • 김제학남경완박서훈
    • A61K31/53A61K31/706C07D405/04A61P35/00
    • C07D405/04
    • PURPOSE: A method for preparing a pre-freeze dried formulation of azacitidine and a freeze dried formulation of azacitidine is provided to improve stability in a solution. CONSTITUTION: A pre-freeze dried formulation of azacitidine is prepared by dissolving azacitidine in a solution containing 40-60%(v/v) of tertiary butanol. The concentration of azacitidine is 0.2-5 mg/ml. The pre-freeze dried formulation is prepared at 5-20 deg.C. A method for preparing a freeze dried formulation of azacitidine comprises: a step of dissolving azacitidine in a solution containing 40-60%(v/v) of tertiary butanol and forming the pre-freeze dried formulation; a step of adding an excipient to the pre-freeze dried formulation; and a step of freeze-drying the formulation. The excipient is polyol including mannitol, sorbitol, or trehalose. [Reference numerals] (AA) Freeze drying cycle; (BB) Temperature(°C); (CC) Time(hours)
    • 目的:提供一种制备阿扎胞定的预冷干燥制剂和阿扎胞苷的冷冻干燥制剂的方法,以提高溶液中的稳定性。 构成:通过将阿扎胞苷溶解在含有40-60%(v / v)叔丁醇的溶液中制备阿扎胞苷的预冷干燥制剂。 阿扎胞苷的浓度为0.2-5mg / ml。 预冷冻干燥制剂在5-20℃下制备。 制备阿扎胞苷的冷冻干燥制剂的方法包括:将阿氨胞苷溶解在含有40-60%(v / v)叔丁醇的溶液中并形成预冷冻干燥制剂的步骤; 将赋形剂添加到预冷冻干燥制剂的步骤; 和冷冻干燥该制剂的步骤。 赋形剂是多元醇,包括甘露醇,山梨糖醇或海藻糖。 (标号)(AA)冷冻干燥循环; (BB)温度(℃); (CC)时间(小时)